# CHINA BIOTECH SERVICES HOLDINGS LIMITED
# 中國生物科技服務控股有限公司

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

## PROFIT ALERT – REDUCTION IN LOSS

This announcement is made by China Biotech Services Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 17.10(2)(a) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**GEM Listing Rules**") and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that based on information currently available to management of the Company and a preliminary review and assessment of the unaudited consolidated management accounts (the "**Management Accounts**") of the Group for the six months ended 30 June 2025 (the "**2025 Interim Period**"), the loss attributable to owners of the Company is expected to be not more than HK$33.0 million for 2025 Interim Period, representing a decrease of approximately 59% as compared to the loss attributable to owners of the Company of HK$79.9 million for the corresponding period in 2024. The significant improvement in operating performance is mainly attributable to an enhanced gross profit margin and reduced administrative expenses resulting from successful implementation of costs control measures and receiving an insurance claim as compensation income of approximately HK$14.0 million in relation to the damages to construction site in Hainan by a rainstorm happened in 2024.

As the Company is in the process of preparing interim results of the Group for the 2025 Interim Period, the information above is only based on management's preliminary review and assessment of the Management Accounts of the Group for the 2025 Interim Period, which have not been reviewed by the auditor or the Audit Committee of the Company and therefore, may be subject to adjustment. The Company expects to announce its unaudited interim results for 2025 Interim Period in late August 2025.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board
**China Biotech Services Holdings Limited**
*Chairman and Executive Director*
**Liu Xiaolin**

Hong Kong, 8 August 2025

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.*